These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15675599)

  • 1. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
    Williams M
    Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599
    [No Abstract]   [Full Text] [Related]  

  • 2. Journal grows suspicious of Vioxx data.
    Wadman M
    Nature; 2005 Dec; 438(7070):899. PubMed ID: 16355178
    [No Abstract]   [Full Text] [Related]  

  • 3. How to avoid future Vioxx-type scandals.
    Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 5. The vexations of Vioxx.
    Sibbald B
    CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
    [No Abstract]   [Full Text] [Related]  

  • 6. Merck VIOXX "warning" is questioned.
    Allen TS; Henderson JH
    Tex Med; 2005 May; 101(5):5-6. PubMed ID: 15948521
    [No Abstract]   [Full Text] [Related]  

  • 7. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

  • 8. Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
    Couzin J
    Science; 2005 Dec; 310(5755):1755. PubMed ID: 16357236
    [No Abstract]   [Full Text] [Related]  

  • 9. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
    Cahana A; Mauron A
    J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
    [No Abstract]   [Full Text] [Related]  

  • 10. Health Canada lukewarm on Vioxx panel findings.
    Murray S
    CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
    [No Abstract]   [Full Text] [Related]  

  • 11. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 12. The sad story of Vioxx, and what we should learn from it.
    Karha J; Topol EJ
    Cleve Clin J Med; 2004 Dec; 71(12):933-4, 936, 938-9. PubMed ID: 15641522
    [No Abstract]   [Full Text] [Related]  

  • 13. Unnecessary withdrawal of Vioxx.
    Adams D
    N Z Med J; 2004 Oct; 117(1204):U1130. PubMed ID: 15505673
    [No Abstract]   [Full Text] [Related]  

  • 14. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 15. Withdrawal syndrome.
    Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials and tribulations. Allegations of waste: the 'seeding' study.
    Malakoff D
    Science; 2008 Oct; 322(5899):213. PubMed ID: 18845743
    [No Abstract]   [Full Text] [Related]  

  • 17. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 18. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of the rofecoxib trials.
    Kozma CM
    Manag Care Interface; 2005 Oct; 18(10):61-2. PubMed ID: 16265937
    [No Abstract]   [Full Text] [Related]  

  • 20. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.